A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

BACKGROUND: Half the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor. (131)I-mIBG is the most widely used form in current use, but is not universally effective. Clinical trials o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundquist, Fredrik, Georgantzi, Kleopatra, Jarvis, Kirsten Brunsvig, Brok, Jesper, Koskenvuo, Minna, Rascon, Jelena, van Noesel, Max, Grybäck, Per, Nilsson, Joachim, Braat, Arthur, Sundin, Mikael, Wessman, Sandra, Herold, Nikolas, Hjorth, Lars, Kogner, Per, Granberg, Dan, Gaze, Mark, Stenman, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960300/
https://www.ncbi.nlm.nih.gov/pubmed/35359899
http://dx.doi.org/10.3389/fped.2022.836230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960300/
https://www.ncbi.nlm.nih.gov/pubmed/35359899
http://dx.doi.org/10.3389/fped.2022.836230

Ejemplares similares